Relation between the number of orphan drugs marketed and the performance of companies.

<p>Calculated from predictions of the fitted pooled OLS regression, with NORPHAN as the explanatory variable of interest, and with all other covariates fixed to average values. Data are presented as the means and 95% confidence bounds (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0164681#pone.0164681.s004" target="_blank">S4 Table</a>).</p

Sensitivity analyses using the number of orphans drugs sold per year (NORPHAN), a non-variant orphan dummy (DORPHAN), and the proportion of orphan drug sales to total sales (SORPHAN).

<p>Sensitivity analyses using the number of orphans drugs sold per year (NORPHAN), a non-variant orphan dummy (DORPHAN), and the proportion of orphan drug sales to total sales (SORPHAN).</p

Mean values of financial variables for orphan and non-orphan drug companies.

<p>Mean values of financial variables for orphan and non-orphan drug companies.</p

The impact of orphan drug company status on company performance.

<p>The impact of orphan drug company status on company performance.</p

Definition of the variables.

<p>Definition of the variables.</p

Summary of the survey format using cancer as an example criterion.

<p>Socio-demographic data were collected to assess associations between respondents’ characteristics and views on the allocation criterion (see <b><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0172971#pone.0172971.t002" target="_blank">Table 2</a></b>).</p

Respondents’ preferences by scenarios: (1) all else being equal and (2) benefit and cost trade-offs.

<p>Respondents’ preferences by scenarios: (1) all else being equal and (2) benefit and cost trade-offs.</p

Text introducing the 12 allocation criteria.

<p>Text introducing the 12 allocation criteria.</p

Allocation criteria explored including cost and benefit trade-off scenarios.

<p>Allocation criteria explored including cost and benefit trade-off scenarios.</p

Multivariate Analysis under assumption of equal treatment effectiveness and costs.

<p>Multivariate Analysis under assumption of equal treatment effectiveness and costs.</p